The medical device firm projects 21%-23% underlying growth for its RNS System while reporting $22.1M in Q1 2026 revenue.
NeuroPace set a 2026 revenue outlook of $99M to $101M, targeting 21%-23% underlying growth for its RNS System. The company reported $22.1 million in total revenue for Q1 2026, with $22 million excluding DIXI Medical, marking an 8% year-over-year increase.
RNS System revenue reached $21.7 million for the quarter. The guidance reflects confidence in sustained demand for its neurostimulation devices amid ongoing market expansion.
No immediate market reaction was disclosed in the earnings call summary.